ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival
September 10, 2022
CureLab Receives $3M from Prominent Biotech Investor Dr. John Ballantyne
March 3, 2023